ICON opens a new office in Boston


Dublin, Ireland, 14 March 2018 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it is opening a new office in Boston, located at 100 Federal Street. The new office will be officially opened by Michael Ring, TD, and Irish Minister for Rural and Community Development, on Thursday, 15th March.

ICON has been operational in the US since 1992 and currently employs over 4,600 professionals from offices in 15 US cities. ICON has grown both organically and through acquisition – since 1992 ICON has acquired 15 US-headquartered companies that have broadened the breadth and depth of its clinical and commercialisation services. ICON’s new office in Boston will enable it to further enhance the partnerships it has with pharma, biotech and medical device companies located in the Massachusetts region. In addition, many of ICON’s 40 employees located in Boston are experts in commercialisation and outcomes strategies which will help customers to generate and communicate treatment safety and value to regulators and healthcare payers.

“We are very excited to open this new space in Boston,” said Ramita Tandon, Executive VP, Commercialisation & Outcomes, ICON plc. “We look forward to partnering with the world renowned cluster of biotech and pharma companies, hospitals, research universities and patient organisations to accelerate the development of medicines that will benefit patients worldwide. Our collaborations will be based on applied innovation, leading edge science and a flexible delivery approach, which are all qualities that have contributed to the strong reputation of the Boston life sciences industry.”

“It is a great pleasure to join ICON this week to celebrate the opening of their new office in Boston,” commented Minister Michael Ring, T.D. “Ireland and the United States enjoy a very successful trade relationship and ICON is one of almost 800 Irish companies operating across all 50 states employing over 100,000 people. As a global leader in clinical research, ICON is a shining example of an Irish company making a difference to the lives of patients worldwide and I wish them continued growth and success.”

Bob Coughlin, President and CEO of MassBio, a not-for-profit organisation that represents and supports the Massachusetts life sciences industry, said: “MassBio is thrilled to welcome ICON to Massachusetts, home to the most innovative life sciences companies in the world. The opportunities to partner with biopharma and medical device companies in the Commonwealth are endless, and I’m confident ICON will contribute to the growth and strength of our cluster, as the industry faces increased pressure to bring new therapies to market faster.” 

About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 38 countries and has approximately 13,250 employees.

ICON Media Contact
Olivia Pimenta
Weber Shandwick
+44 (0)207 067 0557
OPimenta@webershandwick.com

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.